OptimizeRx Corp (NASDAQ: OPRX) is a digital health company that delivers financial, clinical, and brand messaging from pharmaceutical manufacturers to physicians through a distribution network of e-prescribers and electronic health record technology providers. Revenue is generated primarily through content delivery programs, where pharmaceutical brands pay for message distribution directly within clinical workflows, with additional revenue from data subscriptions. The company serves over 100 pharmaceutical manufacturers, with its top five customers representing approximately 47% of revenue for FY2025 and 49% for FY2024. Customer concentration is material: the top 20 pharmaceutical manufacturers, as ranked by Fierce Pharma's 2024 revenue list, generated average revenue of $2,838 thousand per manufacturer for the twelve months ended December 31, 2025, down from $2,976 thousand for the same period in 2024. OptimizeRx's platform includes patented Micro-Neighborhood Targeting and an AI-powered Dynamic Audience Activation Platform (DAAP). Common stock trades on the Nasdaq Capital Market under the symbol OPRX.

Revenue model

Revenue is primarily transactional, generated when pharmaceutical manufacturers pay for content delivery programs distributed through EHR channel partners and direct-to-consumer channels. Secondary revenue comes from data subscriptions, which can be contracted on a standalone basis or alongside content delivery. The company is pursuing a shift toward subscription-based arrangements for DAAP and Micro-Neighborhood Targeting customers to increase revenue predictability.

Products and services

Content delivery programs distributing financial, clinical, and brand messaging through e-prescribers and EHR technology providers. Patented Micro-Neighborhood Targeting (MNT) for precision audience identification. AI-powered Dynamic Audience Activation Platform (DAAP) using machine learning for audience targeting across channels. Data subscriptions sold on a standalone or bundled basis. Set-up and reporting services as complementary offerings.

Customers and end markets

Pharmaceutical manufacturers are the primary customer vertical, with over 100 manufacturers on the platform as of the FY2025 10-K filing. The top five customers represented approximately 47% of FY2025 revenue and 49% of FY2024 revenue. The top 20 pharmaceutical manufacturers by Fierce Pharma's 2024 ranking accounted for a measurable share of total revenue, with average per-manufacturer revenue of $2,838 thousand (twelve months ended December 31, 2025). End market demand is driven by life science industry spend shifting from legacy marketing toward precision digital marketing within clinical settings.

Value-chain role

OptimizeRx sits between pharmaceutical manufacturers and physicians, acting as a distribution intermediary that routes manufacturer messaging through EHR systems and e-prescribing platforms at the point of care. Channel partners are EHR technology providers who carry the content to prescribers.

Source: SEC 10-K, filed 2026-03-12

Industry: Services-Business Services, NEC Peers: Babylon Holdings Ltd TruBridge Inc Sharecare, Inc. Health Catalyst, Inc. HealthStream Inc Pear Therapeutics, Inc. Tabula Rasa HealthCare, Inc. Akili, Inc.